Literature DB >> 21778438

Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.

Philip B Gorelick, Angelo Scuteri, Sandra E Black, Charles Decarli, Steven M Greenberg, Costantino Iadecola, Lenore J Launer, Stephane Laurent, Oscar L Lopez, David Nyenhuis, Ronald C Petersen, Julie A Schneider, Christophe Tzourio, Donna K Arnett, David A Bennett, Helena C Chui, Randall T Higashida, Ruth Lindquist, Peter M Nilsson, Gustavo C Roman, Frank W Sellke, Sudha Seshadri.   

Abstract

BACKGROUND AND
PURPOSE: This scientific statement provides an overview of the evidence on vascular contributions to cognitive impairment and dementia. Vascular contributions to cognitive impairment and dementia of later life are common. Definitions of vascular cognitive impairment (VCI), neuropathology, basic science and pathophysiological aspects, role of neuroimaging and vascular and other associated risk factors, and potential opportunities for prevention and treatment are reviewed. This statement serves as an overall guide for practitioners to gain a better understanding of VCI and dementia, prevention, and treatment.
METHODS: Writing group members were nominated by the writing group co-chairs on the basis of their previous work in relevant topic areas and were approved by the American Heart Association Stroke Council Scientific Statement Oversight Committee, the Council on Epidemiology and Prevention, and the Manuscript Oversight Committee. The writing group used systematic literature reviews (primarily covering publications from 1990 to May 1, 2010), previously published guidelines, personal files, and expert opinion to summarize existing evidence, indicate gaps in current knowledge, and, when appropriate, formulate recommendations using standard American Heart Association criteria. All members of the writing group had the opportunity to comment on the recommendations and approved the final version of this document. After peer review by the American Heart Association, as well as review by the Stroke Council leadership, Council on Epidemiology and Prevention Council, and Scientific Statements Oversight Committee, the statement was approved by the American Heart Association Science Advisory and Coordinating Committee.
RESULTS: The construct of VCI has been introduced to capture the entire spectrum of cognitive disorders associated with all forms of cerebral vascular brain injury-not solely stroke-ranging from mild cognitive impairment through fully developed dementia. Dysfunction of the neurovascular unit and mechanisms regulating cerebral blood flow are likely to be important components of the pathophysiological processes underlying VCI. Cerebral amyloid angiopathy is emerging as an important marker of risk for Alzheimer disease, microinfarction, microhemorrhage and macrohemorrhage of the brain, and VCI. The neuropathology of cognitive impairment in later life is often a mixture of Alzheimer disease and microvascular brain damage, which may overlap and synergize to heighten the risk of cognitive impairment. In this regard, magnetic resonance imaging and other neuroimaging techniques play an important role in the definition and detection of VCI and provide evidence that subcortical forms of VCI with white matter hyperintensities and small deep infarcts are common. In many cases, risk markers for VCI are the same as traditional risk factors for stroke. These risks may include but are not limited to atrial fibrillation, hypertension, diabetes mellitus, and hypercholesterolemia. Furthermore, these same vascular risk factors may be risk markers for Alzheimer disease. Carotid intimal-medial thickness and arterial stiffness are emerging as markers of arterial aging and may serve as risk markers for VCI. Currently, no specific treatments for VCI have been approved by the US Food and Drug Administration. However, detection and control of the traditional risk factors for stroke and cardiovascular disease may be effective in the prevention of VCI, even in older people.
CONCLUSIONS: Vascular contributions to cognitive impairment and dementia are important. Understanding of VCI has evolved substantially in recent years, based on preclinical, neuropathologic, neuroimaging, physiological, and epidemiological studies. Transdisciplinary, translational, and transactional approaches are recommended to further our understanding of this entity and to better characterize its neuropsychological profile. There is a need for prospective, quantitative, clinical-pathological-neuroimaging studies to improve knowledge of the pathological basis of neuroimaging change and the complex interplay between vascular and Alzheimer disease pathologies in the evolution of clinical VCI and Alzheimer disease. Long-term vascular risk marker interventional studies beginning as early as midlife may be required to prevent or postpone the onset of VCI and Alzheimer disease. Studies of intensive reduction of vascular risk factors in high-risk groups are another important avenue of research.

Entities:  

Mesh:

Year:  2011        PMID: 21778438      PMCID: PMC3778669          DOI: 10.1161/STR.0b013e3182299496

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  492 in total

1.  Untangling vascular dementia.

Authors:  W Jagust
Journal:  Lancet       Date:  2001 Dec 22-29       Impact factor: 79.321

2.  White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury.

Authors:  Malee S Fernando; Julie E Simpson; Fiona Matthews; Carol Brayne; Claire E Lewis; Robert Barber; Raj N Kalaria; Gill Forster; Filomena Esteves; Stephen B Wharton; Pamela J Shaw; John T O'Brien; Paul G Ince
Journal:  Stroke       Date:  2006-04-20       Impact factor: 7.914

3.  Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies.

Authors:  Kaarin J Anstey; Chwee von Sanden; Agus Salim; Richard O'Kearney
Journal:  Am J Epidemiol       Date:  2007-06-14       Impact factor: 4.897

4.  Vascular characteristics of patients with dementia.

Authors:  Sandra Morović; Miljenka-Jelena Jurasić; Irena Martinić Popović; Vesna Serić; Marijana Lisak; Vida Demarin
Journal:  J Neurol Sci       Date:  2009-04-16       Impact factor: 3.181

5.  Silent brain infarcts and the risk of dementia and cognitive decline.

Authors:  Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

6.  High total cholesterol levels in late life associated with a reduced risk of dementia.

Authors:  M M Mielke; P P Zandi; M Sjögren; D Gustafson; S Ostling; B Steen; I Skoog
Journal:  Neurology       Date:  2005-05-24       Impact factor: 9.910

7.  Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology.

Authors:  J A Schneider; R S Wilson; J L Bienias; D A Evans; D A Bennett
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

Review 8.  Vascular factors and depression.

Authors:  Emma Teper; John T O'Brien
Journal:  Int J Geriatr Psychiatry       Date:  2008-10       Impact factor: 3.485

9.  The neuropathology of older persons with and without dementia from community versus clinic cohorts.

Authors:  Julie A Schneider; Neelum T Aggarwal; Lisa Barnes; Patricia Boyle; David A Bennett
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

10.  Pravastatin and cognitive function in the elderly. Results of the PROSPER study.

Authors:  Stella Trompet; Peter van Vliet; Anton J M de Craen; Jelle Jolles; Brendan M Buckley; Michael B Murphy; Ian Ford; Peter W Macfarlane; Naveed Sattar; Chris J Packard; David J Stott; Jim Shepherd; Eduard L E M Bollen; Gerard J Blauw; J Wouter Jukema; Rudi G J Westendorp
Journal:  J Neurol       Date:  2009-08-04       Impact factor: 4.849

View more
  1217 in total

Review 1.  Bringing prevention in geriatrics: evidences from cardiovascular medicine supporting the new challenge.

Authors:  Angelo Scuteri; Edward G Lakatta
Journal:  Exp Gerontol       Date:  2012-03-03       Impact factor: 4.032

2.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

Authors:  Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2011-11-20       Impact factor: 17.088

3.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

Review 4.  Cell-to-cell communication and vascular dementia.

Authors:  Hans H Dietrich
Journal:  Microcirculation       Date:  2012-07       Impact factor: 2.628

Review 5.  Getting to the Heart of Alzheimer Disease.

Authors:  Joshua M Tublin; Jeremy M Adelstein; Federica Del Monte; Colin K Combs; Loren E Wold
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

6.  Vascular risk and FDDNP-PET influence cognitive performance.

Authors:  David A Merrill; Prabha Siddarth; Vladimir Kepe; Pushpa V Raja; Nathan Saito; Linda M Ercoli; Karen J Miller; Helen Lavretsky; Susan Y Bookheimer; Jorge R Barrio; Gary W Small
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Innate immunity receptor CD36 promotes cerebral amyloid angiopathy.

Authors:  Laibaik Park; Joan Zhou; Ping Zhou; Rose Pistick; Sleiman El Jamal; Linda Younkin; Joseph Pierce; Andrea Arreguin; Josef Anrather; Steven G Younkin; George A Carlson; Bruce S McEwen; Costantino Iadecola
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 8.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

9.  Hypertension and dementia.

Authors:  Costantino Iadecola
Journal:  Hypertension       Date:  2014-04-28       Impact factor: 10.190

10.  Circulating factors induced by caloric restriction in the nonhuman primate Macaca mulatta activate angiogenic processes in endothelial cells.

Authors:  Anna Csiszar; Danuta Sosnowska; Zsuzsanna Tucsek; Tripti Gautam; Peter Toth; Gyorgy Losonczy; Ricki J Colman; Richard Weindruch; Rozalyn M Anderson; William E Sonntag; Zoltan Ungvari
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-08-17       Impact factor: 6.053

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.